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Abstract
Background: Several accomplishments have been achieved in triple-negative breast cancer (TNBC) research over
the last year. The phase III IMpassion130 trial comparing chemotherapy plus atezolizumab versus chemotherapy
plus placebo brought breast cancer into the immunotherapy era. Nevertheless, despite encouraging results being
obtained in this trial, many open questions remain.
Main body: A positive overall survival outcome was achieved only in PD-L1+ TNBC patients, suggesting a need to enrich
the patient population more likely to benefit from an immunotherapeutic approach. Moreover, it remains unknown
whether single-agent immunotherapy might be a good option for some patients. In this context, the discovery and
implementation of novel and appropriate biomarkers are required. Focusing on the early onset of TNBC, neoadjuvant
trials could represent excellent in vivo platforms to test immunotherapy agents and their potential combinations, allowing
the performance of translational studies for biomarker implementation and improved patient selection.
Conclusion: The aim of our review is to present recent advances in TNBC treatment and to discuss open issues in order
to better define potential future directions for immunotherapy in TNBC.
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Background
Triple-negative breast cancer (TNBC) accounts for ap-
proximately 15–20% of all breast carcinomas and is asso-
ciated with earlier age of onset, aggressive clinical course,
and dismal prognosis compared to hormone receptor-
and HER2-positive breast carcinomas [1]. Given the lack
of effective treatments in this subtype of breast cancer,
several efforts have been conducted in recent years to
increase the therapeutic opportunities for TNBC patients.
Over the last 10 years, considerable evidence has
highlighted the primary role of the immune system in influ-
encing the disease course of TNBC. The presence of
tumor-infiltrating lymphocytes (TILs), assessed by means
of immunohistochemistry staining, is widely recognized as
a predictor of good prognosis in both adjuvant and neoad-
juvant settings of TNBC [2–5]. In addition, a deeper
characterization of immune infiltrates, including the pres-
ence of a high number of cytotoxic (CD8+) TILs or a high
CD8+/FOXP3+ ratio, is able to define TNBC patients with a
better prognosis following neoadjuvant chemotherapy [6].
Along with the presence of TILs, the expression of immune
evasion molecules in the tumor microenvironment, such as
programmed death-ligand 1 (PD-L1), has also been shown
to influence TNBC prognosis [7–10]. These data, together
with the development of new therapeutic agents directed
against immune checkpoint molecules, such as anti-PD-1
and anti-PD-L1 monoclonal antibodies, provide the ration-
ale for the assessment of immunotherapeutic approaches in
TNBC patients.
New and relevant evidence on the implementation of im-
mune checkpoint-based treatments in TNBC has emerged
over the last year, with the results of the IMpassion130 trial
bringing breast cancer into the immunotherapy era. Schmid
et al. [11] demonstrated a substantial overall survival (OS)
benefit in patients with PD-L1-positive (PD-L1+) metastatic
or inoperable locally advanced TNBC through the addition
of the anti-PD-L1 agent atezolizumab to first-line chemo-
therapy with nab-paclitaxel. Approximately 60% of the en-
rolled patients (451 for each treatment arm) experienced
relapse after prior adjuvant/neoadjuvant treatment, while
37% presented with de novo stage IV disease. Additionally,
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approximately 41% of patients in the intent-to-treat (ITT)
population had PD-L1+ disease. At a median follow-up of
12.9months, the median progression-free survival (PFS) in
the ITT population was significantly improved following
the addition of atezolizumab as compared to chemotherapy
alone (7.2 vs. 5.5months); further, among the PD-L1+
population, the respective PFS benefit was more pro-
nounced (7.5 vs. 5.0months). An interim OS analysis
showed that the OS difference was not statistically signifi-
cant in the ITT population (median OS, 21.3months
(atezolizumab + chemotherapy) vs. 17.6months (chemo-
therapy alone)). However, a statistically significant median
OS increase of 9.5months was observed with the addition
of atezolizumab in the PD-L1+ population (25.0 vs. 15.5
months). Moreover, the objective response rate (ORR) was
numerically higher following the addition of atezolizumab
in both the ITT population (56% vs. 46%) and the PD-L1+
population (59% vs. 43%), and more complete responses
were observed with atezolizumab than without (ITT, 7% vs.
2%; PD-L1+ population, 10% vs. 1%).
The above data thus prompt the question of whether im-
munotherapy would truly be transformative for metastatic
TNBC. Despite the encouraging results, various questions
have arisen from the IMpassion130 trial, including how to
appropriately assess tumors for PD-L1 expression given
the benefits derived from atezolizumab treatment in this
patient group, which companion diagnostic is the most
suitable, whether PD-L1 should be tested on immune cells
or tumor cells, whether nab-paclitaxel is the ideal chemo-
therapy partner for immune checkpoint inhibitors (ICIs),
whether an atezolizumab monotherapy arm that might
present a good option for a selected subset of patients was
missed, or assessing what can be learnt from the neoadju-
vant setting. The aim of the present review is to discuss
these open questions in order to define potential future
directions for immunotherapy in TNBC.
How to enrich the TNBC population: PD-L1 and
emerging biomarkers
The positive results obtained in the PD-L1+ subgroup in
the IMpassion130 trial suggest that there is a need to enrich
the study population. However, PD-L1 is not the ideal bio-
marker to select patients for anti-PD1/PD-L1 therapies, as
demonstrated in other cancers. Indeed, only a subset of pa-
tients with PD-L1+ tumors derives a real clinical benefit
from immunotherapeutic treatment, while these therapies
can determine clinical and radiological responses also in
PD-L1− cancers. Considering multiple parameters which
take into consideration both tumor- and patient-related
characteristics, a comprehensive view of immunotherapy in
cancer treatment has been proposed and included in the
framework of the cancer immunogram [12]. Given the po-
tential toxicities of immunotherapy and the highly variable
response across tumor types, as well as the significant
economic burden of immunotherapeutic agents, the identi-
fication and implementation of novel biomarkers that can
predict immunotherapeutic response are urgently required.
PD-L1 expression
PD-L1 expression on tumor cells and/or immune infiltrate
cells is considered a useful biomarker of treatment re-
sponse following anti-PD-1 or anti-PD-L1 therapies [13,
14]. PD-L1 assessment is indeed used as a predictive bio-
marker in other tumor types such as non-small cell lung
cancer [15]. Nevertheless, considerable gaps remain in our
knowledge of the technical aspects of this test, including
the biologic implications and associations of PD-L1
expression, the dynamic changes in expression, the het-
erogeneity in expression on tumor cells and on immune
cells, and prognostic and/or predictive implications [16].
PD-L1 expression in TNBC has been shown to range
from 40 to 65% as tested, in most cases, in immune cells
[7–10, 17]. In the IMpassion130 study, a PD-L1 expression
above 1% in immune cells was used to define the PD-L1+
group [11]. Interestingly, the majority of patients testing as
PD-L1+ in immune cell tumors also had a positive PD-L1
expression on tumor cells [18]. In the Impassion130 bio-
marker subgroup analysis [18], PD-L1 expression on im-
mune cells was positively correlated with CD8+ T cell
number, and both factors were conjointly associated with
increased PFS and OS. However, the best method to test
PD-L1 expression in breast cancer should be harmonized.
Since patients with PD-L1− tumors may still obtain a clin-
ical response with ICIs, PD-L1 expression should be used
only to define a subgroup of patients expected to achieve
greater benefit from ICIs rather than to exclude patients
from treatment [19]. Nevertheless, this is certainly a pro-
vocative statement, underlined by the fact that more ma-
ture data from IMpassion130 and other trials with
pembrolizumab in the same setting are still awaited in
order to be able to draw final conclusions on this issue
(Table 1). Therefore, a variety of potential biomarkers are
now being assessed to predict immunotherapeutic efficacy
in breast cancer beyond PD-L1 expression, including gene
signatures, TILs, tumor mutational burden (TMB), micro-
satellite instability (MSI), and mismatch repair (MMR)
deficiency.
Tumor-infiltrating lymphocytes (TILs)
TILs are a well-known prognostic factor in early-stage
TNBC, positively correlated to both patient survival and
pathological complete response after neoadjuvant chemo-
therapy [2–5]. In addition, TILs have shown a predictive
value in patients with TNBC who were treated with ICI
monotherapy, and their assessment is being implemented
as a stratification factor in breast cancer immunotherapy
trials [20]. As previously described, CD8+ TILs (together
with PD-L1 expression on immune cells) have been
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associated with increased PFS and OS in patients treated
with atezolizumab and nab-paclitaxel in the IMpassion130
trial [18]. Conversely, stromal TILs were only able to
predict PFS benefit. In this context, interesting findings
have been provided by preliminary analyses of the
KEYNOTE-173 trial [21], which is investigating the com-
bination of pembrolizumab and chemotherapy in the
neoadjuvant setting of TNBC. A recent exploratory analysis
of this trial showed that high levels of pretreatment stromal
TILs and PD-L1 expression, reported as a combined posi-
tive score, were significantly associated with higher patho-
logic complete response and overall response rates in
TNBC patients treated with an immunotherapy-based
combination [21].
Table 1 Ongoing phase II/III randomized immunotherapy trials in triple-negative breast cancer
Setting Trial Phase Regimen Patients Status
Neoadjuvant NCT03639948
(NeoPACT)
II Carboplatin + docetaxel + pembrolizumab 100 R
NCT03289819 II Pembrolizumab + Nab-paclitaxel ➔ pembrolizumab +
epirubicin and cyclophosphamide
50 R
NCT03356860
(B-IMMUNE)
II Paclitaxel + epirubicin + cyclophosphamide ±
durvalumab
57 R
NCT02685059
(GeparNuevo)
II Epirubicin + nab-paclitaxel + cyclophosphamide ±
durvalumab
174 ANR
Neoadjuvant/Adjuvant NCT03036488
(KEYNOTE-522)
III Carboplatin + paclitaxel + (anthracycline) +
cyclophosphamide ± pembrolizumab➔ pembrolizumab
1174 ANR
NCT03281954 III Doxorubicin + cyclophosphamide + paclitaxel +
carboplatin ± atezolizumab ➔ atezolizumab
1520 R
NCT03197935
(IMpassion031)
III Doxorubicin + cyclophosphamide + nab-paclitaxel ±
atezolizumab ➔ atezolizumab
204 ANR
Adjuvant only for patients with residual disease
after neoadjuvant chemotherapy
NCT02954874 III Pembrolizumab vs. observation 1000 R
NCT03756298 II Capecitabine ± atezolizumab 284 R
Adjuvant NCT03498716
(IMpassion030)
III Paclitaxel ➔ dose-dense doxorubicin/epirubicin +
cyclophosphamide ± atezolizumab
2300 R
NCT02926196
(A-Brave)
III Avelumab vs. observation 335 R
Locally advanced or metastatic TNBC NCT02768701 II Cyclophosphamide + pembrolizumab 40 ANR
NCT03121352 II Carboplatin, nab-paclitaxel and pembrolizumab 30 R
NCT02819518
(KEYNOTE-355)
III Abraxane or paclitaxel or carboplatin/gemcitabine ±
pembrolizumab
858 ANR
NCT02555657
(KEYNOTE-119)
III Capecitabine, eribulin, gemcitabine, or vinorelbine
as TPC vs. pembrolizumab
600 ANR
NCT03644589 II Cisplatin + pembrolizumab 60 NYR
NCT02755272 II Carboplatin + gemcitabine ± pembrolizumab 87 R
NCT02447003
(KEYNOTE-086)
II Pembrolizumab monotherapy 285 ANR
NCT03125902
(IMpassion131)
III Paclitaxel ± atezolizumab 540 R
NCT03164993
(ALICE)
II Pegylated liposomal doxorubicin + cyclophosphamide ±
atezolizumab
75 R
NCT03206203 II Carboplatin + gemcitabine 185 R
NCT03606967 II Nab-paclitaxel + durvalumab ± neoantigen vaccine 70 NYR
NCT03616886
(SYNERGY)
II Paclitaxel, carboplatin, durvalumab ± oleclumab 171 R
NCT03371017
(IMpassion132)
(early recurrent)
III Carboplatin + gemcitabine or capecitabine ±
atezolizumab
350 R
NCT03167619
(DORA)
II Durvalumab + olaparib 60 R
ANR active, not recruiting, NYR not yet recruiting, TPC therapy per physician’s choice, R recruiting
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Moreover, recent evidence has suggested that qualitative
differences in a TIL subpopulation can better define patient
prognosis [22]. CD8+ T cells with features of tissue-resident
memory T cell differentiation were described in the
lymphocytic infiltrate from breast tumors; the CD8+
tissue-resident memory gene signature subsequently devel-
oped was shown to be significantly associated with
improved patient survival in early-stage TNBC [22].
Gene signatures
In conjunction with TILs, multiple gene signatures have
been studied as surrogates of breast cancer immunogen-
icity. A recent proposal classified breast cancer into four
categories (immunologic constants of rejection (ICR)
ICR1 through ICR4) according to their immune-related
gene expressions, with these categories being correlated
with survival in a retrospective in silico simulation [23].
Specifically, the T helper 1 phenotype (ICR4), associated
with an upregulation of immunoregulatory transcripts
such as PD-L1, PD-1, FOXP3, IDO1, and CTLA-4, was
correlated with a prolonged patient survival. Conversely,
the presence of MAPK pathway disruptions was tightly
associated with an immune-unfavorable phenotype
(ICR1), suggesting that alterations in this pathway are
linked to a negative regulation of immune response in
breast cancer. Interestingly, inhibition of MEK, a crucial
molecule of the MAPK pathway, was able to increase
PD-L1 and MHC class I expression on TNBC cells,
synergizing with PD-L1/PD-1 inhibition in inducing an-
titumor immune responses in TNBC mouse models
[24]. In a further study, a four-gene signature (HLF,
CXCL13, SULT1E1, and GBP1) was found to predict an
increased number of TILs and an improved disease-free
survival in early stage TNBC [25]. However, these gene
signatures have not yet been tested in metastatic TNBC
patients and their role in predicting response to ICIs re-
mains to be defined.
Tumor mutational burden (TMB)
A high TMB has been associated with immunogenicity in
several tumor types [26] and correlated with clinical re-
sponse and increased survival after ICI-based immunother-
apy in patients with melanoma, lung, and colorectal
cancers [27–30]. TMB is a measurement of the number of
nonsynonymous mutations carried by tumor cells [27]. Mu-
tations lead to increased expression of neoantigens in the
context of MHC class I antigens, enhancing the recognition
of cancer cells by T cells. However, limited data regarding
TMB in breast cancer is available. From genomic data, pa-
tients with a favorable immune subclass (based on ‘positive’
immune-infiltrate disposition) along with a high TMB have
a better prognosis [31]. In addition, a higher TMB is more
frequent in TNBC as compared to hormone receptor-posi-
tive subtypes [31]. In contrast with these findings, Samstein
et al. [30] recently published a wide analysis of clinical and
genomic data from more than 1600 advanced cancer pa-
tients treated with ICIs, and reported no significant differ-
ences for breast cancer patients in terms of survival after
immunotherapy treatment. In order to reconcile these dis-
crepancies, we presume that a high TMB alone does not
represent the optimal predictor for immunotherapeutic re-
sponse in breast cancer, suggesting that a finer selection to
enrich the TNBC patient population is required.
MSI and MMR deficiency
Microsatellites are tandem repeats of short DNA se-
quences, abundant throughout the human genome. MSI
is a hypermutator phenotype that occurs in some tumors
with an impaired DNA MMR [32]. MMR deficiency is
known to occur in some tumors, either by somatic
hypermutation of MMR genes, an inherited germline
MMR pathway mutation, or double somatic mutations
in MMR genes [33]. Recently, tumors harboring a high
MSI have been found to be susceptible to ICI-based im-
munotherapy [34, 35], leading to the approval of the
anti-PD-1 agent pembrolizumab for any high MSI or
MMR-deficient unresectable or metastatic solid tumor.
MSI incidence in breast cancer has not yet been fully
elucidated, although high MSI in breast cancers seems
to be found in less than 2% of cases [32]. In a large ana-
lysis of more than 1900 breast cancers [36], high-MSI
tumors presented a low incidence (0.6%); however, a
conjoined analysis of PD-L1 expression, high TMB, and
high MSI selected up to 13% of TNBC patients with at
least one of these alterations. Considering that approxi-
mately 5% of unselected patients with breast cancer
carry a germline BRCA mutation [37], BRCA1 mutations
are predisposed to TNBC, being discovered in 40–50%
of cases [38]. Given the central role of BRCA1 in hom-
ologous recombination-mediated DNA repair [39],
BRCA1-mutated TNBC showed a higher somatic muta-
tional load, a greater number of TILs, and an increased
expression of immunomodulatory genes (PD-1 and
CTLA-4) as compared to BRCA1-wildtype TNBC [40].
Interestingly, the combination of two ICIs (against PD-1
and CTLA-4, respectively) with cisplatin treatment at-
tenuated growth and improved survival in an in vivo
BRCA1-deficient TNBC model, providing a rationale to
implement immunotherapeutic strategies in this sub-
group of TNBC. Several clinical trials are testing a com-
bination of ICIs and PARP inhibitors (e.g., olaparib,
niraparib, and talazoparib) with preliminary data of
activity [41, 42].
Choosing the right chemotherapeutic partner for
immunotherapy
Despite assessments regarding the ideal chemotherapeu-
tic partner for combination treatment with ICIs, various
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questions remain. Nab-paclitaxel was initially selected in
the IMpassion130 study because it facilitates the reduced
use of corticosteroids [43]. However, better agents may
be available to enhance immunogenicity of breast cancer,
including anthracyclines, platinum salts, and other tax-
anes [44]. Chemotherapy can induce multiple immuno-
modulatory changes in the tumor microenvironment,
including increased antigen release by tumor cells,
PD-L1 upregulation, and hyperexpression of immuno-
genic cell surface markers (e.g., MHC class I). Collect-
ively, these modifications might positively influence the
effectiveness of immunotherapy [45, 46]. Specifically,
various chemotherapeutic drugs routinely adopted for
TNBC treatment can induce distinct effects on the
immune system, as described in detail below.
Anthracyclines
Anthracyclines are capable of inducing immunogenic
cell death (ICD), a form of apoptosis which can induce
an effective antitumor immune response through activa-
tion of dendritic cells and specific T cell response [47].
In addition, anthracyclines can also increase proliferation
of CD8+ T cells.
Taxanes
Taxanes can increase TIL recruitment in primary breast
cancer [48]. Moreover, taxanes have been shown to select-
ively decrease T regulatory and myeloid-derived suppres-
sor cells (MDSCs), partially reducing immunosuppression
in the tumor microenvironment [49–51]. We have to
highlight that these immunomodulating effects have been
described for old generation taxanes (docetaxel and pacli-
taxel); no preclinical data regarding nab-paclitaxel’s activ-
ity on the immune system have been reported so far.
Cyclophosphamide
Cyclophosphamide, in conjunction with its well-known
ability to induce ICD, can suppress T regulatory cells and
increase the proliferative capacity of CD8+ T cells and nat-
ural killer cells [52, 53].
Gemcitabine
Gemcitabine can reduce MDSC number and increase
the anti-tumor activity of CD8+ T cells [54, 55].
Platinum salts
Platinum salts have been shown to induce ICD as well as
to increase MHC class I complex on tumor cells [56, 57],
also promoting T cell activation and downregulating
MDSC function [58].
Single agent versus combination immunotherapy
in TNBC
In addition to the results of the IMpassion130 study [11],
other clinical trials are currently evaluating chemotherapy
and immunotherapy combinations in TNBC patients. Pre-
liminary data are available for the open-label phase Ib/II
KEYNOTE-150 trial assessing the combination of eribulin
and pembrolizumab [59]. Among 107 metastatic TNBC
patients (106 evaluable for efficacy), 65 were treatment
naïve, while 41 had received one to two prior lines of ther-
apy. Half of the patients in the study had PD-L1+ TNBC
(45.8%). The ORR of the combination treatment in the
overall population and that in the untreated and pre-
treated patients was 26.4, 29.2, and 22.0%, respectively.
Clinical activity was observed regardless of PD-L1 expres-
sion (ORR 30.6% for PD-L1+ (n = 49) and 22.4% PD-L1−
(n = 49)), even if a greater number of responses was re-
ported in the PD-L1+ subgroup. The PFS and OS across
the full study were 4.2 and 17.7months, respectively. In
the first-line and second−/third-line settings, the median
PFS was 4.9 and 4.1months, respectively, while the me-
dian OS was 17.7 and 18.3months. Considering that
KEYNOTE-150 was a single-arm phase Ib/II trial, the re-
sults are largely comparable with those obtained from the
IMpassion130 study.
While the combinations of atezolizumab with nab-pacli-
taxel and pembrolizumab with eribulin produced substan-
tial benefits in TNBC patients, we hypothesize that some
subgroups of breast cancer patients (e.g., those with high
TILs or high PD-L1 expression) may derive benefit from
ICI monotherapy; evidence of this is available from phase
I/II clinical trials (Table 2).
In a phase I clinical trial [63], atezolizumab led to a
higher ORR in the first-line setting (24%) compared to a
second-line or greater setting (6%). In first-line patients,
median OS was 17.6 months. Interestingly, patients with
PD-L1 expression in at least 1% of tumor-infiltrating im-
mune cells had higher ORRs (12 vs. 0%) and a longer
OS (10.1 vs. 6.0 months) than those with PD-L1 expres-
sion in less than 1% of tumor-infiltrating immune cells.
High levels of immune cells (> 10%) were independently
associated with higher ORR and longer OS.
In the phase Ib KEYNOTE-012 trial [60], the anti-PD-1
agent pembrolizumab achieved an ORR of 18.5% in meta-
static TNBC patients, with a median OS of 11.2months. Of
note, 15.6% of the subjects enrolled in this trial were treat-
ment naïve. Similarly, in the phase II trial KEYNOTE-086
(cohort-A) [61], pembrolizumab led to an ORR and disease
control rate of 5.3 and 7.6%, respectively, in pretreated
TNBC patients; median PFS and OS were 2.0 and 9.0
months, respectively. Patients with PD-L1+ tumors showed
only a slight increase in response rate. Additionally,
approximately 40% of patients received more than three
lines of therapy for metastatic disease.
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Finally, in the phase I JAVELIN trial [62], the anti-
PD-L1 agent avelumab produced an ORR of 5.2% in heav-
ily pretreated metastatic TNBC patients. A trend toward a
higher ORR was seen in patients with PD-L1+ versus
PD-L1− tumor-associated immune cells in the overall
population (16.7% vs. 1.6%) and in the TNBC subgroup
(22.2% vs. 2.6%).
As expected, a high response to single-agent anti-PD-1/
PD-L1 immunotherapy has been observed in previously
untreated metastatic TNBC patients. These findings sug-
gest that ICIs should be more active in less heavily
pretreated patients, opening the door to testing these
strategies in an early TNBC setting.
Moving immunotherapy to early TNBC
Previous evidence suggests that early TNBC presents with
a reduced immunosuppressive phenotype compared to
metastatic cases [65]. Therefore, there is increasing interest
in testing immunotherapeutic strategies in both neoadju-
vant and adjuvant settings. Data is available on the efficacy
of ICIs in early settings obtained in stage III melanoma and
non-small cell lung cancer [66–68]. In TNBC, various
neoadjuvant studies are currently ongoing (Table 1).
Neoadjuvant trials represent an excellent in vivo labora-
tory to test immunotherapeutic agents and their potential
combination with other drugs, including chemotherapy,
targeted agents, and other immunomodulatory agents. The
possibility to obtain baseline biopsies and to reassess both
tumor response and changes in the tumor microenviron-
ment at established time-points can lead to the discovery of
novel biomarkers for patient stratification. Innovative find-
ings obtained in the neoadjuvant setting could then be
translated in adjuvant and metastatic settings. However, an
additional important point of discussion in the neoadjuvant
Table 2 Completed studies with immune checkpoint inhibitors in triple-negative breast cancer
Trial Setting Drug Patients Results Ref.
Single agent immunotherapy
KEYNOTE-012
NCT01848834
Advanced PD-L1+ TNBC Pembrolizumab 10 mg/kg Q2W 27 ORR, 18.5%
Median PFS, 1.9 months
Median OS, 11.2 months
[60]
KEYNOTE-086
NCT02447003
Advanced, untreated, any PD-L1
TNBC (cohort A)
Advanced, untreated PD-L1+
TNBC (cohort B)
Pembrolizumab 200mg Q3W Cohort A: 170
Cohort B: 84
ORR Cohort A, 4.7%
ORR Cohort B, 22.6%
Median PFS Cohort A,
2 months
Median PFS Cohort B,
2.1 months
Median OS Cohort A,
8.9 months
Median OS Cohort B,
19.2 months
[20,
61]
JAVELIN
NCT01772004
TNBC unselected for PD-L1 (68.8%
had PD-L1+ tumors)
Avelumab
10mg/kg every 2 weeks
58 ORR, 5.2% (22.2% in
PD-L1+)
Median PFS, 1.5 months
Median OS, 9.2 months
[62]
NCT01375842
Advanced TNBC unselected for PD-L1
(65.7% had PD-L1+ tumors)
Atezolizumab 15 or 20mg/kg, or at a
1200-mg flat dose, Q3W
116 ORR, 10% (12.7% in
PD-L1+)
Median PFS, 1.4 months
by RECIST
Median PFS, 1.9 months
by irRECIST
Median OS, 8.9 months
[63]
Combination of immunotherapy and chemotherapy
KEYNOTE-150
NCT02513472
Advanced TNBC unselected for PD-L1 Eribulin ± pembrolizumab
200mg Q3W
107 ORR, 26.4% (30.6%
in PD-L1+)
Median PFS, 4.2 months
Median OS, 17.7 months
[59]
IMpassion130
NCT02425891
Untreated metastatic TNBC
unselected for PD-L1
Nab-paclitaxel ± atezolizumab
840mg Q2W
902 (451 treated
with atezolizumab)
ORR, 56% (58.9%
in PD-L1+)
Median PFS, 7.2 months
Median PFS, 7.5 months
(PD-L1+)
Median OS, 21.3 months
Median OS, 25 months
(PD-L1+)
[11,
64]
PD-L1+ expression in stroma or ≥ 1% of tumor cells by immunohistochemistry
irRECIST immune-related Response Evaluation Criteria In Solid Tumors, ORR objective response rate, OS overall survival, PD-L1 programmed death-ligand 1, PFS
progression-free survival, Q2W every 2 weeks, Q3W every 3 weeks, RECIST Response Evaluation Criteria In Solid Tumors, TNBC triple-negative breast cancer
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setting should be raised – when defining endpoints for im-
munotherapy studies, should OS and event-free survival be
preferred instead of pathologic complete response? In other
solid tumors, the real benefit of ICI administration is repre-
sented by an increase in OS, and therefore pathologic
complete response might not be the ideal surrogate end-
point to approve these agents in the neoadjuvant setting.
The selection of adequate endpoints is strongly encouraged
for future clinical trials testing immunotherapy in TNBC.
Regarding the adjuvant setting, TNBC patients at high
risk for relapse and who are less likely to be cured by the
current standard of treatment could benefit the most by
the addition of ICIs. For instance, patients with TNBC
who do not achieve pathologic complete response after
neoadjuvant chemotherapy have a worse prognosis, and
capecitabine administration in the post-neoadjuvant set-
ting is the only standard of care for these patients [69].
The addition of ICIs could improve cure rates in this set-
ting; some trials are exploring this possibility (Table 1).
Conclusion
The harnessing in clinical practice of immune checkpoint-
based treatment has radically changed the therapeutic ap-
proaches for several tumor types. Nevertheless, until the
IMpassion130 trial, few studies had addressed immunother-
apeutic strategies for the treatment of breast cancer. The
IMpassion130 trial first explored the metastatic setting,
with lessons being learned primarily from phase I trials.
First, ICIs should be combined with other agents to im-
prove benefit. Second, immunotherapy should be imple-
mented in the first-line setting of metastatic treatment to
improve response rates. Third, patients should be stratified
according to specific biomarkers. Additionally, early-stage
breast cancer appears to be even more appealing than the
metastatic setting for the introduction of ICIs, both in the
neoadjuvant and adjuvant settings, since primary tumors
seem more immunogenic than metastatic sites. The mul-
tiple ongoing trials may shed light on breast cancer im-
mune response biomarkers and help determine whether a
multidimensional immunogram could predict efficacy
better than the current PD-L1-based unidimensional
immunogram.
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